Transgene Biotek Limited
Bombay Stock ExchangeTotal Valuation
Transgene Biotek Limited carries a market capitalization of 232.61M, placing it among publicly traded companies globally. Its enterprise value stands at 319.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 232.61M |
| Enterprise Value | 319.70M |
Share Statistics
Transgene Biotek Limited currently has 75.77M shares outstanding.
| Shares Outstanding | 75.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 70.49, and the price-to-book ratio stands at 0.20.
| PE Ratio | N/A |
| PS Ratio | 70.49 |
| PB Ratio | 0.20 |
| P/TBV Ratio | 8.10 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Transgene Biotek Limited trades at an EV/EBITDA multiple of 1,507.29 and an EV/FCF ratio of 30.16. The EV/Sales ratio of 151.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,507.29 provides insight into valuation relative to core operating earnings.
| EV / Sales | 151.30 |
| EV / EBITDA | 1,507.29 |
| EV / EBIT | 1,507.29 |
| EV / FCF | 30.16 |
Financial Position
Transgene Biotek Limited maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 204.57, indicating elevated leverage, while an interest coverage ratio of -0.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.08 |
| Quick Ratio | 0.00 |
| Debt / Equity | 204.57 |
| Debt / EBITDA | -23.08 |
| Interest Coverage | -0.70 |
Financial Efficiency
| Return on Equity (ROE) | -2.18 |
| Return on Assets (ROA) | -1.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Transgene Biotek Limited's stock has declined approximately -36.30705% over the past 52 weeks. The 50-day moving average sits at 3.05, while the 200-day moving average is 3.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -36.30705% |
| 50-Day Moving Average | 3.05 |
| 200-Day Moving Average | 3.06 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Transgene Biotek Limited generated 2.11M in revenue and converted that into -16.53M in net income, yielding earnings per share of -0.22. EBITDA reached -7.42M, while operating income came in at -7.42M.
| Revenue | 2.11M |
| Gross Profit | 2.11M |
| Operating Income | -7.42M |
| Pretax Income | -16.53M |
| Net Income | -16.53M |
| EBITDA | -7.42M |
| EBIT | -7.42M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
Transgene Biotek Limited holds 608,000.00 in cash and equivalents against 171.37M in total debt, resulting in a net debt position of 170.76M. Total book value stands at 757.70M, with working capital of -122.29M providing operational flexibility.
| Cash & Cash Equivalents | 608,000.00 |
| Total Debt | 171.37M |
| Net Debt | 170.76M |
| Equity (Book Value) | 757.70M |
| Book Value Per Share | 10.07 |
| Working Capital | -122.29M |
Margins
Transgene Biotek Limited operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -351.40 and net profit margin of -782.25 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -351.40 |
| Pretax Margin | -782.25 |
| Profit Margin | -782.25 |
| EBITDA Margin | -351.40 |
Scores
Transgene Biotek Limited posts an Altman Z-Score of -0.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.06 |